IN-CLASS TRANSITION (ICT)
FROM PARENTERAL BORTEZOMIB
TO ORAL IXAZOMIB PROTEASOME
INHIBITOR (PI) THERAPY INCREASES
THE FEASIBILITY OF LONG-TERM PI
TREATMENT AND BENEFIT FOR
NEWLY DIAGNOSED MULTIPLE
MYELOMA (NDMM) PATIENTS
IN AN OUTPATIENT SETTING

VIEW POSTER

A COMPREHENSIVE HIGH RESOLUTION
SCRNA-SEQ ANALYTICAL PLATFORM
FOR CHARACTERIZING HUMAN
HEMATOPOIETIC STEM/PROGENITOR
CELLS STATES IN EX VIVO
DRUG PRODUCTS

VIEW POSTER

UPDATED OVERALL SURVIVAL OF
ELTANEXOR FOR THE TREATMENT OF
PATIENTS WITH HYPOMETHYLATING
AGENT REFRACTORY MYELODYSPLASTIC
SYNDROME

VIEW POSTER